Definitive Contract 75N93018C00023
Award Date 9/20/18
Potential Completion Date 7/22/25
Potential Value $40M
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Honolulu, HI 96817, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
24
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $149,868.00 Firm Fixed Price SBIR Phase I contract awarded by the U.S. Army Medical Command to Hawaii Biotech, Inc., a small business biotechnology company. The contract supports the research and development of prophylactic vaccines for infectious diseases, specifically targeting Anthrax intoxication, botulism, and West Nile Virus. Hawaii Biotech has previously received federal grants from the National Institute of Allergy and Infectious Diseases (NIAID) to fund its vaccine research...
- This is a $6,821,012.21 Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The contract is for the development of a broad spectrum monoclonal antibody-based therapeutic for botulism, a biological threat. The contract has no set-aside designation and the ultimate completion date is September...
- This is a federal contract award from the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract, valued at $124,523,123.01, is for the production of ANTHIM (obiltoxaximab), a medication used for the treatment of anthrax. The contract was awarded to Elusys Therapeutics Inc., a for-profit biomedical research and development company headquartered in Parsippany, New Jersey. Elusys...
- This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services (HHS), to Elusys Therapeutics Inc. The contract, valued at $13,853,653.00, is for biomedical research and development services, ranging from basic to advanced capabilities. The contract is a Definitive Contract with a Cost No Fee pricing type, and does not have a set-aside designation. The period of performance runs from September 28,...
- This is a $18,576,013.05 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute located in Seattle, Washington. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant infections, and emerging infectious diseases, under NIAID's Broad Agency Announcement (BAA) Research Area 001. AAHI...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Biocryst Pharmaceuticals Inc., a biotechnology company specializing in small molecule drugs for rare diseases. The $47,755,722.77 cost-plus-fixed-fee contract is for the development of medical countermeasures for biodefense and emerging infectious diseases. The contract has a base period from September 16, 2013, to September 15, 2017, with two option periods...
- This is a $30,704,925.57 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Achaogen, Inc., a for-profit organization. The contract was awarded on September 1, 2008, with a period of performance through August 27, 2016, and was not set aside for any specific business type. The contract was awarded under a Broad Agency Announcement (BAA) solicitation, BAA...
- This is a $3,624,974 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Trius Therapeutics, Inc. for the "DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has a period of performance from September 16, 2013 to September 15, 2015, with a ceiling value of $845,876.06. There is no set-aside for this award....
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Emory University. The $3,458,502.19 cost-no-fee contract is for "TARGETING THERAPEUTICS DEVELOPMENT TO RELIEVE BOTTLENECKS: OPTIMIZONG LEAD THERAPEUTIC COMPOUNDS AGAINST INFECTIOUS PATHOGENS." It has a period of performance through October 31, 2018. The contract is not designated as a set-aside. The contract has several...
- This is a definitive, cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods. The contract, valued at $213,045,738.00, is for preclinical development services to support infectious disease research and product development initiatives. The contract does not have a set-aside designation. ABL has been awarded numerous federal contracts and grants,...